Journal of Neurosurgery Pediatrics · 2016 · 44 citations · 5 references
MedicineOncologyPediatricsMolecular OncologyNeuro-oncologyPediatric OncologyBrain TumorsPediatric Brain TumorsPediatric Cancer GeneticsPediatric Neuro-oncologyPediatric Neurosurgical OncologyPediatric TumorsBraf V600 MutationsGenetic TestingIndividualized Treatment RegimensMapk Pathway MutationsMitogen-activated Protein Kinase CascadesMitogen-activated Protein Kinase KinasePediatric Low-grade GliomaPediatric Neuro-oncology Trials
Brain tumors are the most common solid tumor in childhood, and astrocytomas account for the largest proportion of these tumors. Increasing sophistication in genetic testing has allowed for the detection of specific mutations within tumor subtypes that may represent targets for individualized tumor treatment. The mitogen-activating protein kinase (MAPK) pathway and, more specifically, BRAF mutations have been shown to be prevalent in pediatric pilocytic astrocytomas and may represent one such area to target. Herein, the authors describe 2 cases of inoperable, chemotherapy-resistant pediatric pilocytic astrocytomas with a documented response to trametinib, an MAPK pathway inhibitor. While these cases were not treated in the setting of a clinical trial, their data support further ongoing clinical trial investigation to evaluate the safety and efficacy of this agent in pediatric low-grade gliomas.
5
Genevieve Schindler, David Capper, Jochen Meyer et al. · Acta Neuropathologica · 2011 · 1K citations
Jacquelyn J. Roth, Mariarita Santi, Avrum N. Pollock et al. · Brain Pathology · 2014 · 44 citations · Full text
The BRAF kinase domain promotes the development of gliomas in vivo
Clifford Shin, Allie H. Grossmann, Sheri L. Holmen et al. · Genes & Cancer · 2015 · 19 citations · Full text